Brucellosis Vaccine Market – Type (RB51, S19, B19 vaccines), Vaccine (DNA, Subunit, Vector Vaccines), Animal Type (Cattle, Sheep, Goat), End-user (Veterinary Clinics & Hospitals, Animal Care Centers), Global Forecast (2024 – 2032)

Brucellosis Vaccine Market Size

Brucellosis Vaccine Market size in 2023 accounted for USD 242.4 million and is projected to grow at CAGR of 4.9% between 2024 and 2032. One of the major drivers is the increasing prevalence of brucellosis in livestock, leading to significant economic losses in the agricultural sector.
 

Additionally, the rising awareness about the importance of vaccination among farmers and veterinarians is boosting the demand for brucellosis vaccines. Government initiatives and programs aimed at controlling and eradicating brucellosis are also fueling market growth. Furthermore, advancements in vaccine development technologies, such as recombinant DNA technology are expected to drive innovation in the brucellosis vaccine market, leading to the development of more effective and safer vaccines, thereby boosting the market growth.
 

Brucellosis vaccine is a type of animal vaccines developed to prevent brucellosis, a bacterial infection caused by various species of Brucella bacteria, including Brucella abortus, Brucella melitensis, and Brucella suis. These vaccines are primarily used in veterinary medicine to protect livestock, such as cattle, goats, sheep, and pigs, from contracting the disease.
 

Brucellosis Vaccine Market Trends

• The growth in livestock production, driven by rising global demand for animal products such as meat, milk, and dairy, creates a significant market opportunity for brucellosis vaccines. With larger livestock populations, there is a higher risk of brucellosis transmission, making vaccination a crucial preventive measure.
   
• Livestock producers are increasingly investing in disease prevention strategies, including vaccination, to safeguard their herds and ensure the sustainability of their operations. This trend fuels demand for brucellosis vaccines, leading to market growth.
   
• Additionally, brucellosis outbreaks not only pose significant economic losses to livestock producers but also raise public health concerns due to the zoonotic nature of the disease.
   
• Thus, as the prevalence of brucellosis continues to rise, there is a heightened urgency to implement effective vaccination programs and control measures, further fueling the market growth.
   

Brucellosis Vaccine Market Analysis

Based on type, the market is segmented into RB51 vaccines, S19 vaccines, B19 vaccines, and other types. The RB51 vaccines segment dominated the market with 43.7% of market share in 2023.
 

• RB51 vaccine has demonstrated high efficacy in protecting against brucella abortus infection in cattle. Studies have shown that RB51 vaccination significantly reduces the risk of abortion and transmission of brucella abortus to other animals, making it a preferred choice among livestock producers and veterinarians.
   
• In addition to this, RB51 vaccine provides long-lasting immunity and is considered safer than the older S19 vaccine, leading to high adoption of this vaccine, thereby fostering the growth of this segment.
   

Based on vaccine, the brucellosis vaccine market is classified into DNA vaccines, subunit vaccines, vector vaccines, and recombinant vaccines. The DNA vaccines segment held highest market share and is anticipated to grow at CAGR of 4.8% over the forecast period.
 

• The DNA vaccines segment has emerged as the dominant segment in the market, largely due to its innovative technology and exceptional performance.
   
• Owing to several advantages it offers including high immunogenicity, safety, and potential for cross-protection against diverse brucella species or strains, propels the growth of this segment.
   
• Moreover, DNA vaccines boast excellent stability and long shelf-life, making them convenient for storage, transportation, and administration in various environmental conditions. Thereby, significantly driving the growth of this segment.

Based on animal type, the brucellosis vaccine market is divided into cattle, sheep, goat, and other animal types. The cattle segment accounted for significant market share and is anticipated to reach USD 216.7 million by 2032.
 

• The dominance of the cattle segment in the market can be attributed to the economic importance of cattle in global food production, their high susceptibility to brucella abortus infections, the zoonotic nature of brucellosis, and regulatory mandates requiring vaccination.
   
• With cattle serving as a reservoir for brucella abortus and the potential risk of transmission to humans, preventing brucellosis in cattle is imperative, hence contributing to the growth of this segment.
   

Based on end-user, the brucellosis vaccine market is categorized into veterinary clinics & hospitals, animal care centers, and other end-users. The veterinary clinics & hospitals segment was valued at USD 146.4 million in 2023.
 

• The veterinary clinics & hospitals segment dominated the market due to its pivotal role as a centralized hub for vaccine distribution, administration, and expertise.
   
• These facilities serve as trusted sources of veterinary advice and guidance, offering specialized knowledge on disease prevention, including brucellosis vaccination protocols.
   
• Moreover, veterinary clinics and hospitals provide convenient access to brucellosis vaccination services, particularly in rural and remote areas where access to veterinary care may be limited, through vaccination clinics, mobile veterinary services, and on-farm visits.

North America brucellosis vaccine market was valued at USD 99.4 million in 2023 and is predicted to reach USD 150.7 million by the end of the forecast timeframe.
 

• North America boasts a significant livestock population, particularly cattle, which is highly susceptible to brucella abortus infection.
   
• With large cattle herds in countries like the U.S. and Canada, the risk of brucellosis transmission is heightened, necessitating widespread vaccination to prevent disease outbreaks and economic losses in the livestock industry.
   
• The region also benefits from advanced veterinary infrastructure, including well-established veterinary clinics, hospitals, and diagnostic laboratories equipped to handle brucellosis vaccination programs.
   

U.S. brucellosis vaccine market is anticipated to witness growth at 4.7% CAGR over the forecast years.
 

• The U.S. has stringent regulatory standards for animal health and food safety enforced by agencies such as the United States Department of Agriculture (USDA) and the Animal and Plant Health Inspection Service (APHIS).
   
• Regulatory mandates and vaccination requirements compel livestock producers to prioritize brucellosis vaccination to maintain market access, ensure compliance with regulatory standards, and meet export requirements.
   
• Furthermore, the U.S. leads in technological advancements in vaccine development, research, and innovation. Ongoing investments in research and development drive the development of novel vaccine formulations, delivery systems, and vaccination strategies, enhancing the efficacy and safety of brucellosis vaccines in the US market. Such aforementioned factors boost the growth of this market.
   

Germany held a significant position in global brucellosis vaccine market.
 

• According to National Institutes of Health, the annual incidence of brucellosis in Germany was 0.38/1,000,000 population, of which 75% are travel associated. With the increasing incidence of brucellosis Germany prioritizes brucellosis prevention as part of its public health initiatives, aiming to protect livestock populations and mitigate the risk of zoonotic transmission to humans.
   
• In addition, factors such as advanced veterinary infrastructure, strict regulatory standards, high livestock density, and technological advancements influence the growth of market in Germany.
   

India market is predicted to witness growth at considerable growth rate during the forecast period.
 

• According to 20^th Livestock Census, total livestock population in India were 535.78 million in 2019. Of which total number of cattle in the country were 192.49 million in 2019.
   
• This large livestock population, particularly the significant number of cattle, in India acts as a key driver in the market, highlighting the importance of vaccination efforts to safeguard animal health, ensure food security, and mitigate economic losses in the agricultural sector.
   

Brucellosis Vaccine Market Share

The brucellosis vaccine industry is highly competitive characterized by the presence of several key players, including pharmaceutical companies, biotechnology firms, and veterinary vaccine manufacturers. These companies engage in research, development, production, and distribution of brucellosis vaccines, striving to gain market share and maintain competitiveness through innovation, strategic partnerships, and regulatory compliance.
 

Brucellosis Vaccine Market Companies

Prominent players operating in the brucellosis vaccine industry include:

• Ceva
• Colorado Serum Company
• Creative Biolabs
• CZ Vaccines
• Fivet Animal Health
• Hester Biosciences Limited
• Indian Immunologicals Ltd.
• Jordan Bio-industries Center
• Laboratories Tornel
• Merck & Co., Inc.
• VETAL Animal Health Products Inc.
• Veterinary Technologies Corporation
   

Brucellosis Vaccine Industry News:

• In September 2020, Hester Biosciences entered into an agreement to acquire indigenous technology from ICAR-IVRI (Indian Council of Agricultural Research - Indian Veterinary Research Institute) for the development of the Brucella Abortus S19 Delta Per vaccine. This strategic initiative helped the company to broaden their product portfolio and generate revenue.
   

The brucellosis vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• RB51 vaccines
• S19 vaccines
• B19 vaccines
• Other types

Market, By Vaccine

• DNA vaccines
• Subunit vaccines
• Vector vaccines
• Recombinant vaccines

Market, By Animal Type

• Cattle
• Sheep
• Goat
• Other animal type

Market, By End-user

• Veterinary clinics & hospitals
• Animal care centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa